Study of the Efficacy, Safety and Tolerability of Oral CE... | NCT00236119

NCT00236119

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
CEP-701 20mg	Experimental	Patient Cohort 1	Drug: CEP-701 20mg
CEP-701 40mg	Experimental	Patient Cohort 2	Drug: CEP-701 20mg Drug: CEP-701 40mg
CEP-701 60mg	Experimental	Patient Cohort 3	Drug: CEP-701 20mg Drug: CEP-701 40mg Drug: CEP-701 60mg
CEP-701 80mg	Experimental	Patient Cohort 4	Drug: CEP-701 20mg Drug: CEP-701 40mg Drug: CEP-701 60mg Drug: CEP-701 80mg

Interventions

Name	Type	Description	Arm Group Labels	Other Names
CEP-701 20mg	Drug	Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Physicians Static Global (PSGA) Score	The primary objective of the study is to evaluate the efficacy of oral escalating dosages of CEP-701 at 20, 40, 60, and 80 mg given twice daily (bid) in achieving complete or nearly clearing of psoriasis in patients with severe, recalcitrant, plaque-type psoriasis, as assessed by the Physicians Static Global (PSGA) at baseline and at the end of treatment. A PSGA score of 0 is defined as no evidence of plaque elevation, no evidence of erythema, and no evidence of scaling. A PSGA score of 5 is defined as plaque elevation (2.5 mm or greater)dusky to deep red coloration, very thick tenacious scale predominates.	87 Days

Secondary Outcomes

Measure	Description	Time Frame
PSGA Change from Baseline	Change from baseline to the end of treatment (ie, day 85±2 PSGA measured on a scale of 0 to 5 at the end of treatment severity of itch measured on a severity scale of 0 to 5 at the 85±2 days) 0 meaning No itching - 5 Severe; constant itching; distressing; frequent disturbance of sleep; interferes with activities	87 days

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Patients are included in the study if all of the following criteria are met:

the patient is at least 21 years old.
The patient has sever, recalcitrant, plaque-type psoriasis and has failed at least 1 systemic therapy (for the purposes of this study psoralen with ultraviolet light A is considered to be a systemic therapy).
The patient has psoriatic involvement of at least 10% of BSA.
The patient has a PSGA score of 4 or greater.
The patient, if a woman, is surgically sterile or 2 years postmenopausal, or if of childbearing potential is currently using a medically accepted method of contraception, and agrees to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of contraception include: abstinence, steroidal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method, or intrauterine device (IUD).
The patient, if a main, is surgically sterile, or if capable of producing offspring, is currently using an approved method of birth control, and agrees to continued use of this method for the duration of the study (and for 60 days after taking the last dose of CEP-701 because of the possible effects on spermatogenesis).
The patient must be willing and able to comply with study procedures and restrictions and willing to return to the clinic for the follow-up evaluation as specified in this protocol.

Exclusion Criteria:

The patient has received treatment with systemic psoriasis treatments (specifically, retinoids, methotrexate, cyclosporine A, etanercept, efalizumab, other biological agents or other immunomodulators) within 4 weeks, or UV based therapy within 2 weeks, or alefacept within 6 weeks of the planned 1st day of study treatment.
The patient has received treatment with potent CYP3A4 inhibitors including cyclosporine, clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole, erythromycin, clarithromycin, and troleandomycin, human immunodeficiency virus (HIV) protease inhibitors, or nefazodone within 1 week (7 days) of the planned 1st day of study treatment.
The patient is currently receiving warfarin.
The patient has hypersensitivity to CEP-701 or any component of CEP-701.
The patient has one or more of the following serum chemistry values as determined at the screening visit (visit 1):
bilirubin levels greater than 2 times the upper limit of normal (ULN)
ALT or AST levels greater than 2 times the ULN
serum creatinine levels or more than 2mg/dL
The patient requires current treatment for HIV with protease inhibitors.
The patient is taking medication for a clinical diagnosis of gastrointestinal ulceration or has experienced melena or hematoemesis in the previous 3 weeks.
The patient is a woman who is pregnant or lactating.
The patient has received treatment with an investigation drug within 4 weeks of the planned 1st day of study treatment.

Facility	Status	City	State	ZIP	Country	Contacts
Wake Forest University		Winston-Salem	North Carolina	27157	United States
Texas Dermatology Rsch Inst

ID	Term
D017444	Skin Diseases, Papulosquamous
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases